Planning for access in some EU markets is often left until after an asset is reimbursed in the EU5 markets.
Understanding the key considerations and evidentiary requirements for those markets ahead of time could help:
ensure development of a robust evidence package
aid launch sequence planning
secure optimum market access across Europe.
This webinar provides an overview of HTA and market access processes in several EU markets: *Bulgaria, the Czech Republic, Finland, the Netherlands, and Romania.
It explores the key considerations for manufacturers ahead of launch in these markets to drive operational excellence and secure timely quality access.
How global market access teams can provide effective partnership for local markets by maximizing investment in market access preparedness.
Why greater understanding of HTA submission requirements and key drivers for market access across EU markets can aid launch sequence planning and help global teams to provide valuable support for local teams.
How operational excellence facilitates optimal time to access, quality of access achieved, and time sustained with quality access before loss of exclusivity.
Key learning aims
Gain an appreciation of HTA assessment processes and submission requirements in Bulgaria, the Czech Republic, Finland, the Netherlands, and Romania
Identify the decision-makers and key stakeholders.
Learn how operational excellence and the PRMA Navigator® digital application can help maximize the likelihood for success in these markets.
This webinar is for those who want to understand the key considerations for access in European markets (outside of EU5), ahead of launch. It is also relevant for global and regional access and pricing professionals who want to drive operational excellence and timely quality access.
As a member of the PRMA Navigator® team, Claire leads delivery of PRMA Navigator® projects. She has more than 15 years’ experience in market access, with a particular interest in defining evidence generation strategies and developing value demonstration materials, including payer marketing materials, product value dossiers, HTA submissions, and HEOR publications. Claire has provided strategic and editorial support across a number of therapeutic areas, including oncology, arthropathies, infection, diabetes, and neuroscience. She holds a PhD in Cancer Studies from the University of Manchester.
Vanya has more than 5 years’ experience in market access consultancy. At PRMA Consulting, she has worked across a range of different projects, including strategic landscape assessments using the PRMA Healthcheck® digital application to develop evidence generation roadmaps for market access, primary research with payers and KOLs, research on the role of real-world evidence in HTA, and drafting HTA submissions using the PRMA Navigator® application. Vanya has expertise across a range of therapeutic areas including oncology, cardiovascular, and metabolic disorders, and rare disease. Vanya holds a PhD from King’s College London and an MSc from Imperial College London.
Jonathan has several years’ experience in market access consulting and has been involved in a broad range of projects at PRMA Consulting. He is a member of the PRMA Navigator® team and has helped generate partial HTA submissions for a number of European markets across a range of indications. He is also a content manager for the PRMA Navigator®, responsible for adapting submission templates from major HTA agencies for use with the PRMA Navigator®. Other project experiences have included work on developing global value materials, evidence generation planning, and situation analyses. Jonathan is the author of several publications in leading neuroscience and behavioral pharmacology journals. He has a PhD in Behavioral Pharmacology from the University of Cambridge.
Adriana Dacheva holds a PhD in Social Medicine and Health Management. In 2017, she completed her postgraduate qualification in Health Management. Adriana Dacheva has 7 years of experience working on HTA dossier preparation and more specifically as a budget impact analyst. Specializes additionally in Glasgow, Barcelona, Copenhagen, Milan, Washington, Vienna, and taking part in courses organized by ISPOR in the field of HTA and, in particular, in budgetary impact area, risk-sharing agreements. Since the beginning of 2020, she has been actively involved in projects related to value-based healthcare (VBHC) in Bulgaria. She is teaching HTA and VBHC at medical universities and business schools (MU Pleven, AUBG, Charles University Prague,) and is a co-author of books, articles on HTA, VBHC.
Dr Slaveyko Djambazov has international expertise as a consultant on health policy, HTA, VBHC. He is a medical doctor, holding a PhD in HTA, an MBA from the American University in Bulgaria (AUBG), and a master’s degree in public health. Dr Djambazov also completed an executive course at Harvard Business School for VBHC with Prof Porter and Prof Kaplan. He is teaching HTA and VBHC at medical universities and business schools (MU Pleven, AUBG, Charles University Prague, St Andrews Scotland) and is a co-author of books on HTA, health economics, clinical trials, VBHC, >100 research papers. Dr Djambazov is the founder and managing director of HTA Ltd. For the last 8 years, HTA Ltd. has prepared >800 analyses for >80 multinational companies. Since 2017, Dr Djambazov has been actively working with investment groups, governments, and royal families on large investment projects in Africa and Central/Southeast Asia.
Duration: 30 minutes.
Driving BioPharma Access in Europe: Insights for Markets Outside of EU5
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.